DEPLOYDatabase

Company

Intuitive Surgical

surgical robotintuitivesurgical.com

Dominant surgical-robotics maker (NASDAQ: ISRG; founded 1995, Sunnyvale CA) of the da Vinci teleoperated surgical robots and the Ion robotic bronchoscopy…

Track Intuitive Surgical
Founded
1995
HQ
Sunnyvale, California, USA
Status
public (NASDAQ: ISRG)

The verified answer

As of Sep 2026, DEPLOY verifies Intuitive Surgical: 2 models, 16 deployments across 6 regions, $231.0M raised, 56 active incidents. 10 sources back the record.

Regulatory status4 FDA 510(k) clearances11 FDA recalls1 FDA warning letter

Intuitive Surgical holds 4 FDA 510(k) clearances and has 11 FDA recalls and 1 FDA warning letter on record, per the DEPLOY registry.

See all 16 filings
PublicNASDAQ: ISRG

CategorySurgical robots

Funding

$231.0M

Models

2

Deployments

16

Patents

6

Overview

Dominant surgical-robotics maker (NASDAQ: ISRG; founded 1995, Sunnyvale CA) of the da Vinci teleoperated surgical robots and the Ion robotic bronchoscopy system; 11,000+ da Vinci installed worldwide.

Verified record

Verified deployments
16 deployments on file
Active incidents
56 incidents on file

Valuation of record

Company-claimed
$2.3B (reported, approximate)as of Jun 2000

Priced roundIPO post-money

See the full valuations ranking →

Key facts

Installed base

11,395 da Vinci (1,464 da Vinci 5) + 1,041 Ion (SEC 10-Q, Q1 2026).

Gating events

da Vinci 5 FDA-cleared Mar 14 2024; Ion FDA-cleared Feb 2019.

Stock listing

NASDAQ: ISRG

Market position

Dominant surgical-robotics maker

da Vinci product type

Teleoperated surgical robot

Ion product type

Robotic bronchoscopy system

Hero image candidate

upload.wikimedia.org (source: Wikimedia Commons, license: CC BY-SA 4.0)

Manufacturingsee manufacturing →

Vertically integrated — manufactures da Vinci Xi, SP, and 5 systems in-house at Sunnyvale campus (surgeon console, patient side cart, instruments). 99%+ uptime.

Data & sources

Company filings

2

Press releases

1

News coverage

1

Patent documents

6

10 sources backing this record.View all →

Models (2)

View all models →

Current platform

Ion Endoluminal System

Intuitive Surgical's Ion Endoluminal System is a robotic-assisted bronchoscopy platform for minimally invasive biopsy of peripheral lung nodules. It uses an ultra-thin, shape-sensing maneuverable catheter with PlanPoint CT-based airway planning to reach lesions deep in the peripheral lung. FDA 510(k) cleared in February 2019 and commercially deployed across US hospitals, with subsequent AI and advanced-imaging integration clearances.

surgicalView model →

Current platform

da Vinci (and Ion)

Intuitive Surgical (NASDAQ: ISRG; founded 1995, Sunnyvale, California) is the dominant incumbent and verified gold standard of surgical robotics. Its da Vinci platform spans the multi-port X and Xi systems, the SP single-port system, and the fifth-generation da Vinci 5, which the FDA cleared via 510(k) on March 14, 2024 with a headline Force Feedback sensing feature, alongside the Ion endoluminal robotic bronchoscopy system cleared in February 2019. As of its SEC Form 10-Q for the quarter ended March 31, 2026, the verified installed base was 11,395 da Vinci systems, up 12 percent year over year and including 1,464 da Vinci 5 units, plus 1,041 Ion systems, up 22 percent, with worldwide procedures growing about 17 percent. Surgical robotics sits in the registry as a deliberate axis-extension: physical AI operating in the medical regulatory regime, where FDA clearance is the verified gating event for maturity, and Intuitive clears it across multiple platforms and generations, placing it at production maturity. On AI substance, da Vinci is a master-slave teleoperated system with shipped analytics-grade AI such as Case Insights and machine-vision interface features, and Force Feedback is a shipped sensing feature rather than autonomy; autonomous suturing and tissue manipulation via vision-language models are research demonstrations on da Vinci hardware, not shipped features, and the 4,000-mile telesurgery demonstration is investigational. The widely cited 43-percent-less-force figure is preclinical and marketing-sourced rather than an outcomes-verified clinical result.

surgicalView model →

Intuitive Surgical on the deployment map

View the global map

16 verified deployments across 6 regions, newest verified Jun 2026. Explore where Intuitive Surgical's robots are operating, by place and type.

Free to use on your site, with a link back to DEPLOY.

View the full Intuitive Surgical deployment record →

Free to use on your site, with a link back to DEPLOY.

Relationships

PPublic MarketInvestorIIntuitive SurgicalCustomer

Explainers

Plain-language answers to the questions people ask about Intuitive Surgical, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.Read the full explainer →
What is Intuitive Surgical and the da Vinci surgical robot?
Intuitive Surgical is the verified-at-scale anchor of the surgical robotics cohort. Per SEC 10-Q registry source-of-truth, installed base is 11,395 da Vinci systems + 1,041 Ion systems; the installed base dwarfs combined competitor installed base. da Vinci 5 was FDA-cleared March 2024 as the current product generation; Ion is a separate robotic-bronchoscopy product line. Architecture is teleoperated baseline with shipped analytics AI; autonomous suturing work on da Vinci hardware is research demos, not shipped product. Maturity: production. Per DEPLOY's framework, da Vinci is the gold standard verified deployment all other surgical entrants are measured against.Read the full explainer →
Which surgical robot is most deployed?
Intuitive Surgical's da Vinci: 11,106 systems installed worldwide as of Dec 31, 2025 per its 10-K, roughly an order of magnitude ahead of every soft-tissue competitor. Stryker Mako is the only credible challenger on procedure volume, via orthopedics.Read the full explainer →
What is the cheapest surgical robot?
Distalmotion's Dexter, at roughly $500K-$1M (2025 analyst estimate), is the cheapest FDA-cleared general soft-tissue surgical robot on record, undercutting da Vinci ($1.5M-$2.5M) and Versius ($750K-$1M).Read the full explainer →

Current leadership (3)

Founders (4)

See all founders across the registry →

Board (3)

Former / Previously (5)

Safety record

47 recalls and 9 incidents on record (2 catastrophic, 4 critical, 39 serious, 9 moderate, 2 minor). Most recent: Jun 2026.

catastrophic
2
critical
4
serious
39
moderate
9
minor
2
recall
47
regulatory action
4
other
2
injury
2
fatality
1

Most recent: Jun 2026

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Incidents affecting Intuitive Surgical (56)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Operator customers (1)

Recent coverage

Intuitive Surgical in third-party press

Surgeons use da Vinci surgical robot to perform common cardiac surgery

Aug 17, 2026

PVHMC First in the Region to Introduce State-of-the-Art da Vinci 5 Surgical Robots

Aug 3, 2026

This Surgical Robot Could Transform the Operating Room

Aug 2, 2026

Peers

49 peers across 1 segment. Every Intuitive Surgical competitor derived from shared form-factor and application-domain edges.

surgical robot(49)

28 companies in this segment · moderately_concentrated (HHI 2056.2102191459944) · leader Mazor Robotics at 3317%